S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|The Lancet Publishes Two Phase 3 Studies Showing Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With Serious Genetic Disorders That Cause High Cholesterol|
|Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels|
|VYTORIN® (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study|
|Amgen To Highlight New Data For Investigational Cholesterol-Lowering Medication Evolocumab|
|Alnylam and The Medicines Company Announce Initiation of Phase 1 Clinical Trial for ALN-PCSsc, a Subcutaneously Administered Investigational RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia|
|Esperion Therapeutics Announces Positive Top-Line Phase 2b Results for ETC-1002, An Investigational Therapy for Patients with Hypercholesterolemia|
|Genzyme and Isis Present KYNAMRO® Clinical Data at the American Heart Association|
|Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Third Quarter 2014 Financial Results|
|Acasti Reports Successful CaPre(R) Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C|
|Esperion Therapeutics to Present at BioCentury’s NewsMakers in the Biotech Industry Conference|
Click above to view more mutual fund data and stats for ldl - Ldlc.com.